New subgroup data from the phase 3 ROSELLA trial show that adding relacorilant (Lifyorli) to nab-paclitaxel significantly improves survival for patients with platinum-resistant ovarian cancer, regardless of prior taxane treatment history.
With a median follow-up of 24.8 months, patients receiving the combination therapy achieved a median overall survival of 16.0 months, compared with 11.9 months for those treated with nab-paclitaxel alone, representing a 35% reduction in the risk of death. The regimen also improved progression-free survival, reducing the risk of disease progression or death by 30%, with median progression-free survival of 6.5 months versus 5.5 months.
The survival benefit remained consistent across patient subgroups, including those with both short and long taxane-free intervals and regardless of whether taxane therapy had been part of the most recent treatment regimen. Nearly all patients in the study had previously received a taxane-based therapy.
The combination was generally well tolerated, with no new safety concerns identified. Researchers reported no relacorilant-related fatal adverse events or cases of adrenal insufficiency. These findings further support the March 2026 FDA approval of relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer.